[Form 4] Sangamo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Glazer Capital, LLC and managing member Paul J. Glazer filed a Schedule 13G disclosing a passive stake in Dun & Bradstreet Holdings, Inc. (NYSE: DNB).

• Shares owned: 22,750,000 common shares.
• Ownership percentage: 5.10 % of outstanding stock, crossing the 5 % reporting threshold.
• Authority: 0 shares with sole voting/dispositive power; full authority is shared between the reporting persons.
• Filer status: Glazer Capital files as an investment adviser under Rule 13d-1(b)(1)(ii)(E); position is certified as non-activist.
• Trigger date: 17 Jul 2025; filing executed 24 Jul 2025.

No other group members, subsidiaries, or control intentions are identified. The disclosure signals incremental institutional interest but does not imply strategic influence or imminent corporate actions.

Positive

• Institutional endorsement: A reputable investment adviser now holds 5.1 % of DNB, signalling confidence in the issuer.

Negative

• No activist agenda: 13G status indicates Glazer Capital will not push for strategic changes, limiting upside catalysts tied to governance reform.

Insights

Equity Analyst

TL;DR: Passive 5.1 % stake by Glazer Capital adds institutional support but lacks activist catalyst; neutral valuation impact.

Glazer Capital’s 22.75 M-share position brings DNB another sizable professional investor, yet Schedule 13G rules restrict efforts to influence management. The holding neither introduces takeover optionality nor immediate balance-sheet changes. At roughly 5 %, Glazer can exit quietly without filing Form 144 sales notices, so liquidity overhang remains low. For valuation, the news marginally improves float quality but is unlikely to affect cash flows, multiples, or guidance.

Corporate Governance Specialist

TL;DR: Filing is compliance-driven; shared voting power limits governance pressure—impact classified as routine.

Because Glazer Capital uses a 13G rather than 13D, it explicitly disavows control ambitions. Shared rather than sole authority further reduces board-room leverage. No poison-pill thresholds are breached, so DNB’s governance posture is unchanged. Investors should interpret this as standard portfolio allocation, not a signal of strategic activism.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dubois-Stringfellow Nathalie

(Last) (First) (Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND CA 94084

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP-CHIEF DEVELOPMENT OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		F		31,866(1)	D	$0.4798	767,881(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

2. Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 15,030 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby, Attorney-in-Fact	07/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DNB shares does Glazer Capital own?

They beneficially own 22,750,000 common shares.

What percentage of DNB does the 22.75 M shares represent?

The position equals 5.10 % of the company’s outstanding stock.

Is Glazer Capital seeking control of Dun & Bradstreet?

No. The filing is on Schedule 13G, which is for passive ownership without control intent.

Does Glazer Capital have sole voting power in DNB?

No. It reports 0 shares with sole voting/dispositive power; all authority is shared.

When was the stake large enough to trigger this filing?

The event date requiring disclosure was 17 Jul 2025.

What type of entity is Glazer Capital according to the SEC classification?

It is an investment adviser under Rule 13d-1(b)(1)(ii)(E).